Claims for Patent: 10,525,022

Summary for Patent: 10,525,022

Title:	Pharmaceutical composition for treating cancer, containing lactate metal salt
Abstract:	The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy.
Inventor(s):	Kim; Hwan Mook (Daejeon, KR), Jeong; Keun Yeong (Seoul, KR), Sim; Jae Jun (Seoul, KR), Jang; Yeong Su (Incheon, KR)
Assignee:	METIMEDI PHARMACEUTICALS CO., LTD. (Incheon, KR)
Application Number:	15/629,445
Patent Claims:	1. A method of inhibiting metastasis of cancer in a subject in need thereof, comprising administering an effective amount of calcium lactate to the subject, wherein the calcium lactate is administered subcutaneously, intravenously, or intratumorally as a unit dose of a pharmaceutical composition comprising the calcium lactate in a concentration of 2.5 mM to 25 mM. 2. The method of claim 1, wherein the subject has lung cancer, breast cancer, colorectal cancer, stomach cancer, brain cancer, pancreatic cancer, thyroid cancer, skin cancer, bone cancer, lymphoma, uterine cancer, cervical cancer, kidney cancer, liver cancer, or melanoma. 3. The method of claim 1, wherein the calcium lactate is administered as the only active ingredient. 4. The method of claim 1, further comprising treating the subject with a radiation therapy. 5. The method of claim 4, wherein the subject is irradiated with an amount of radiation of 2 Gy per day to 10 Gy per day. 6. The method of claim 1, further comprising administering to the subject one or more additional anticancer drugs. 7. The method of claim 6, wherein the one or more additional anticancer drugs are selected from the group consisting of Imatinib, 5-Fluorouracil, Irinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab, Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, 5-indane sulfonamide, cinnamic acid, and combinations thereof. 8. The method of claim 6, further comprising treating the subject with a radiation therapy. 9. The method of claim 1, wherein the administering delivers an amount of calcium lactate to cancer stem cells of the subject sufficient to induce a morphology change of the cancer stem cells. 10. The method of claim 1, wherein the administering delivers an amount of calcium lactate to cancer cells of the subject sufficient to inhibit angiogenesis. 11. The method of claim 1, wherein the administering delivers an amount of calcium lactate to cancer cells of the subject sufficient to inhibit expression of vascular endothelial growth factor (VEGF) or hypoxia-inducible factor-1 alpha (HIF-1 alpha) in the cancer cells. 12. The method of claim 1, wherein the administering delivers an amount of calcium lactate to cancer cells of the subject sufficient to inhibit glycolysis of glucose in the cancer cells. 13. The method of claim 1, wherein the administering delivers an amount of calcium lactate to cancer cells of the subject sufficient to increase pyruvate, increase lactate dehydrogenase B (LDH-B), or increase alpha-ketoglutarate in the cancer cells. 14. The method of claim 1, wherein the subject is a human. 15. A method of treating cancer in a subject in need thereof, comprising administering calcium lactate to the subject, wherein the calcium lactate is administered subcutaneously, intravenously, or intratumorally as a unit dose of a pharmaceutical composition comprising the calcium lactate in a concentration of 2.5 mM to 25 mM, and wherein the administering delivers an effective amount of calcium lactate to cancer cells of the subject to: a) decrease expression of beta-catenin as a cancer growth factor, poly ADP ribose polymerase (PARP), hypoxia-inducible factor-1 alpha (HIF-1 alpha), or vascular endothelial growth factor (VEGF) in the cancer cells; b) suppress glycolysis of glucose in the cancer cells; or c) inhibit angiogenesis. 16. The method of claim 15, wherein the administering delivers an effective amount of calcium lactate to cancer cells of the subject to increase pyruvate, increase lactate dehydrogenase B (LDH-B), or increase alpha-ketoglutarate in the cancer cells. 17. The method of claim 15, further comprising irradiating the subject or administering to the subject one or more additional anticancer drugs. 18. The method of claim 17, wherein the one or more additional anticancer drugs are selected from the group consisting of Imatinib, 5-fluorouracil, Irinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab, Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, 5-indane sulfonamide, cinnamic acid, and combinations thereof. 19. The method of claim 17, comprising irradiating the subject with an amount of radiation of 2 Cry per day to 10 Gy per day. 20. A method of treating cancer in a subject in need thereof, consisting essentially of administering an effective amount of calcium lactate to the subject, wherein the calcium lactate is administered subcutaneously, intravenously, or intratumorally as a unit dose of a pharmaceutical composition comprising the calcium lactate in a concentration of 2.5 mM to 25 mM. 21. The method of claim 20, wherein the cancer is a metastatic cancer. 22. The method of claim 20, wherein the cancer is lung cancer, breast cancer, colorectal cancer, stomach cancer, brain cancer, pancreatic cancer, thyroid cancer, skin cancer, bone cancer, lymphoma, uterine cancer, cervical cancer, kidney cancer, liver cancer, or melanoma. 23. A liquid dosage form pharmaceutical composition comprising 2.5 mM to 25 mM calcium lactate and an anticancer drug selected from the group consisting of Imatinib, 5-fluorouracil, Irinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab, Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, 5-indane sulfonamide, cinnamic acid, and combinations thereof as active ingredients and a pharmaceutically acceptable carrier, excipient, or diluent.

Details for Patent 10,525,022

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-12-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-12-29